# An Updated Narrative Review on the Therapeutic Potential of Resveratrol in the Treatment of Cancer

**Authors:** Mohammad Ashraful Islam, Al Amin, Md. Abdul Aziz, Md. Mahabubur Rahaman, Jakir Hossain, Jakir Ahmed Chowdhury, Mohammad Safiqul Islam

PMC · DOI: 10.1002/hsr2.71995 · Health Science Reports · 2026-03-02

## TL;DR

This review explores how resveratrol, a natural compound, may help treat various cancers by affecting cell growth and death pathways.

## Contribution

The paper provides an updated review of resveratrol's molecular mechanisms and therapeutic potential across multiple cancer types.

## Key findings

- Resveratrol influences cell cycle arrest and activates apoptosis in various cancers.
- It suppresses metastasis through multiple signaling pathways.
- In vivo studies show resveratrol reduces tumor development in animal models.

## Abstract

Cancer is a significant global health challenge, affecting millions of people every year. Overall survival rates have improved over time, but some patients exhibit treatment resistance, prompting ongoing research to find suitable and effective sensitizers. Resveratrol, a natural polyphenolic compound, has demonstrated significant effects in inhibiting the growth and spread of cancer. However, the molecular mechanisms and applications of resveratrol remain unclear.

In this updated narrative review, we aimed at discussing the role and related molecular mechanisms of resveratrol in various cancers and providing an overview of its therapeutic potential for the treatment and prevention of these cancers.

We conducted an extensive literature search across four major databases, including PubMed, Google Scholar, Web of Science, and ScienceDirect, to identify all relevant articles.

Resveratrol is a naturally occurring polyphenolic compound, specifically a stilbene, found in significant quantities in grapes, berries, peanuts, and various other plants. Resveratrol significantly contributes to the reduction of various human cancers, including those of the breast, cervix, thyroid, prostate, brain, skin, colon, bone, and ovarian cancers. Resveratrol has been shown to influence cell cycle arrest, activate apoptosis, and suppress metastasis, all of which are achieved through various signaling pathways. Additionally, several in vivo studies have shown promising results suggesting it may reduce tumor development and extend lifespan in animal cancer models, among other benefits.

This review indicates that resveratrol could serve as a prototype for developing more efficacious and less toxic therapeutic agents for the treatment of various cancers.

## Linked entities

- **Chemicals:** resveratrol (PubChem CID 5056)
- **Diseases:** cancer (MONDO:0004992), breast cancer (MONDO:0004989), cervix cancer (MONDO:0005131), thyroid cancer (MONDO:0002108), prostate cancer (MONDO:0005159), brain cancer (MONDO:0001657), skin cancer (MONDO:0002898), colon cancer (MONDO:0002032), bone cancer (MONDO:0002129), ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** MIR4435-2HG (MIR4435-2 host gene) [NCBI Gene 541471] {aka AGD2, LINC00978, MIR4435-1HG, MORRBID, lncRNA-AWPPH}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, KLK11 (kallikrein related peptidase 11) [NCBI Gene 11012] {aka IEKD, PRSS20, TLSP}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 72508] {aka 2610318I15Rik, P70S6K1, S6K, S6K-beta-1, S6K1, p70 S6K-alpha}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, MIR200C (microRNA 200c) [NCBI Gene 406985] {aka MIRN200C, mir-200c}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, RECK (reversion inducing cysteine rich protein with kazal motifs) [NCBI Gene 8434] {aka ST15}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, JAG1 (jagged canonical Notch ligand 1) [NCBI Gene 182] {aka AGS, AGS1, AHD, AWS, CD339, CMT2HH}, DLL4 (delta like canonical Notch ligand 4) [NCBI Gene 54567] {aka AOS6, delta4, hdelta2}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, PIAS3 (protein inhibitor of activated STAT 3) [NCBI Gene 10401] {aka ZMIZ5}, HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, WNT2 (Wnt family member 2) [NCBI Gene 7472] {aka INT1L1, IRP}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, PIP5K1C (phosphatidylinositol-4-phosphate 5-kinase type 1 gamma) [NCBI Gene 23396] {aka LCCS3, PIP5K-GAMMA, PIP5K1-gamma, PIP5Kgamma}, GADD45A (growth arrest and DNA damage inducible alpha) [NCBI Gene 1647] {aka DDIT1, GADD45}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, Nup62 (nucleoporin 62) [NCBI Gene 18226] {aka D7Ertd649e, Nupc1, p62}, NOTCH2 (notch receptor 2) [NCBI Gene 4853] {aka AGS2, HJCYS, hN2}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, Chuk (conserved helix-loop-helix ubiquitous kinase) [NCBI Gene 12675] {aka Chuk1, Fbx24, Fbxo24, IKBKA, IKK alpha, IKK1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, WIF1 (Wnt inhibitory factor 1) [NCBI Gene 11197] {aka WIF-1}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** PDAC (MESH:C537768), inflammation (MESH:D007249), neurodegenerative disorders (MESH:D019636), Prostate Cancer (MESH:D011471), Melanoma (MESH:D008545), GBM (MESH:D005910), Cervical Cancer (MESH:D002583), small-cell lung cancer (MESH:D055752), mitochondrial dysfunction (MESH:D028361), Pancreatic Cancer (MESH:D010190), Lung Cancer (MESH:D008175), Multiple Myeloma (MESH:D009101), adenocarcinoma (MESH:D000230), cancer (MESH:D009369), diabetes (MESH:D003920), pancreatitis (MESH:D010195), edema (MESH:D004487), lung adenocarcinoma (MESH:D000077192), obesity (MESH:D009765), skin cancer (MESH:D012878), PTC (MESH:D000077273), carcinogenesis (MESH:D063646), FTC (MESH:D018263), NSCLC (MESH:D002289), squamous cell carcinomas (MESH:D002294), cervical malignancies (MESH:D002575), colon adenocarcinoma (MESH:D003110), metastasis (MESH:D009362), death from (MESH:D003643), precancerous lesions (MESH:D011230), Thyroid Cancer (MESH:D013964), Colorectal Cancer (MESH:D015179), cardiovascular disease (MESH:D002318), endocrine resistance (MESH:D004700), cytotoxicity (MESH:D064420), bone sarcoma (MESH:D001847), Breast Cancer (MESH:D001943), uveal melanoma (MESH:C536494), Ovarian Cancer (MESH:D010051), Chondrosarcoma (MESH:D002813), Glioblastoma (MESH:D005909), brain tumor (MESH:D001932)
- **Chemicals:** bromodeoxyuridine (MESH:D001973), agar (MESH:D000362), stilbene (MESH:D013267), arsenic trioxide (MESH:D000077237), rapamycin (MESH:D020123), 3,4,4'-trihydroxy-trans-stilbene (MESH:C570432), water (MESH:D014867), phenol (MESH:D019800), pifithrin-alpha (MESH:C121565), styrene (MESH:D020058), 3,5,4'-Trihydroxystilbene (MESH:D000077185), PD 98059 (MESH:C093973), aglycones (MESH:C458179), iodide (MESH:D007454), ROS (-), cisplatin (MESH:D002945), curcumin (MESH:D003474), dUTP (MESH:C027078), cyclodextrin (MESH:D003505), gefitinib (MESH:D000077156), etoposide (MESH:D005047), cerulenin (MESH:D002569), Polyphenols (MESH:D059808), steroid hormone (MESH:D013256), erlotinib (MESH:D000069347), lipid (MESH:D008055), melanin (MESH:D008543), NAD(+) (MESH:D009243), alcohol (MESH:D000438)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Veratrum grandiflorum (species) [taxon 203092], Arachis hypogaea (goober, species) [taxon 3818], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Curcuma longa (turmeric, species) [taxon 136217], Human papillomavirus 16 (serotype) [taxon 333760]
- **Mutations:** serine/threonine, Rs16260, Rs1042522
- **Cell lines:** PA-1 — Homo sapiens (Human), Transformed cell line (CVCL_E800), SiHa — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_0032), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), DU-145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), NIH3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), U373 glioma — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_2818), A549 lung cancer — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_3008), HT-144 — Homo sapiens (Human), Wolman disease, Induced pluripotent stem cell (CVCL_UD78), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953729/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953729/full.md

## References

139 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953729/full.md

---
Source: https://tomesphere.com/paper/PMC12953729